Aerpio Pharmaceuticals, Inc. Purchase Agreements
5 Contracts & Agreements
- Amendment No.3 to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product, effective as of July 31, 2024, by and between Aadi Bioscience, Inc. and... (Filed With SEC on November 6, 2024)
- Amendment No.2 to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product, dated April 1, 2024, by and between Aadi Bioscience, Inc. and Fresenius... (Filed With SEC on May 8, 2024)
- Form of Securities Purchase Agreement, dated September 22, 2022, by and among the Company and the Purchasers (Filed With SEC on September 22, 2022)
- Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product, dated as of January 13, 2022, by and between the Company and Fresenius Kabi, LLC (Filed With SEC on May 12, 2022)
- Asset Purchase Agreement dated August 17, 2021, by and between Aerpio Pharmaceuticals, Inc. and EyePoint Pharmaceuticals, Inc (Filed With SEC on August 23, 2021)
